Patent · US Active

Somatic stem cells

US8986679B2 · kind B2 · utility

0Cited by
6References
15Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMay 16, 2013
Grant dateMar 24, 2015
Priority date
Expiry dateMay 16, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2506/11
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method of treating a cellular proliferative disorder in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, differentiating the somatic stem cells to dendritic cells in a medium containing GCSF, SCF, EGF, PDGF, bFGF, and IL-3, purifying the dendritic cells, contacting the dendritic cells thus purified with a cancer antigen, and administrating an effective amount of the dendritic cells presenting the cancer antigen to a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.